keyword
MENU ▼
Read by QxMD icon Read
search

Type 2 diabetes and basal insulin

keyword
https://www.readbyqxmd.com/read/29785837/more-patients-reach-glycaemic-control-with-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide-iglarlixi-than-with-basal-insulin-at-12-weeks-of-treatment-a-post-hoc-time-to-control-analysis-of-lixilan-o-and-lixilan-l
#1
Juan Frias, Manuel Puig Domingo, Luigi Meneghini, Raffaele Napoli, Minzhi Liu, Erika Soltes Rak, Vanita R Aroda
This post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O) or basal insulin (LixiLan-L). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <7% or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan-Meier method. In LixiLan-O and -L, 60% and 46% of patients, respectively, reached HbA1c <7% with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar...
May 21, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29773934/iglarlixi-a-new-once-daily-fixed-ratio-combination-of-basal-insulin-glargine-and-lixisenatide-for-the-management-of-type-2-diabetes
#2
Debbie Hinnen, Jodi Strong
Background: Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia, weight gain, or other objections may lead to clinical inertia, whereby therapy is not intensified and patients live with uncontrolled hyperglycemia and increased risk for complications. Initiation of injectable therapy with a glucagon-like peptide (GLP)-1 receptor agonist and/or basal insulin is a recommended option for patients with type 2 diabetes inadequately controlled on one or more oral agents...
May 2018: Diabetes Spectrum: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29773932/effectiveness-and-tolerability-of-therapy-with-once-weekly-exenatide-versus-basal-insulin-among-injectable-naive-patients-with-type-2-diabetes-in-a-real-world-setting-in-the-united-states
#3
Anita M Loughlin, Qing Qiao, Anthony P Nunes, Stephen M Ezzy, Laura Yochum, C Robin Clifford, Robert V Gately, David D Dore, John D Seeger
A propensity-matched cohort study compared injectable-naive patients with type 2 diabetes initiating exenatide once weekly (EQW) or basal insulin (BI), from 2012 through 2015, within a U.S. electronic health record database. A1C and weight were obtained as observed or multiply imputed values at baseline and quarterly for 1 year (Q1-Q4). Hypoglycemia and gastrointestinal symptoms were identified using diagnostic codes and clinical notes. EQW ( n = 2,008) and BI ( n = 4,016) cohorts were comparable at baseline (mean A1C and weight: EQW, 8...
May 2018: Diabetes Spectrum: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29769704/effect-of-protocatechuic-acid-on-insulin-responsiveness-and-inflammation-in-visceral-adipose-tissue-from-obese-individuals-possible-role-for-ptp1b
#4
Paulina Ormazabal, Beatrice Scazzocchio, Rosaria Varì, Carmela Santangelo, Massimo D'Archivio, Gianfranco Silecchia, Annunziata Iacovelli, Claudio Giovannini, Roberta Masella
BACKGROUND/OBJECTIVES: The occurrence of chronic inflammation in visceral adipose tissue (VAT) in obese subjects precipitates the development of insulin resistance and type 2 diabetes (T2D). Anthocyanins and their main metabolite protocatechuic acid (PCA) have been demonstrated to stimulate insulin signaling in human adipocytes. The aim of this study was to investigate whether PCA is able to modulate insulin responsiveness and inflammation in VAT from obese (OB) and normal weight (NW) subjects...
May 16, 2018: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/29766635/efficacy-and-safety-of-mk-1293-insulin-glargine-compared-with-originator-insulin-glargine-lantus-in-type-1-diabetes-a-randomized-open-label-clinical-trial
#5
Philip D Home, Raymond L H Lam, Wendy L Carofano, Gregory T Golm, Roy Eldor, Michael F Crutchlow, Michael C Marcos, Julio Rosenstock, Priscilla A Hollander, Baptist Gallwitz
AIMS: Comparison of the efficacy and safety of MK-1293 insulin glargine (Mk-Gla; 100 U/ml) with originator insulin glargine, Lantus (Sa-Gla) in people with type 1 diabetes mellitus (T1DM). MATERIALS AND METHODS: This phase 3, randomized, active-controlled, open-label, 52-week study enrolled 508 people with T1DM (HbA1c ≤ 11.0%; 97 mmol/mol) taking basal and prandial insulin. Participants were randomized 1:1 to once-daily Mk-Gla (n=245) or Sa-Gla (n=263). Dose titration of basal insulin was by a pre-breakfast plasma glucose dosing algorithm...
May 15, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29766601/functional-high-intensity-exercise-training-ameliorates-insulin-resistance-and-cardiometabolic-risk-factors-in-type-2-diabetes
#6
Ciarán E Fealy, Stephan Nieuwoudt, Julie A Foucher, Amanda R Scelsi, Steve K Malin, Mangesh Pagadala, Lauren A Cruz, Miranda Li, Michael Rocco, Bartolome Burguera, John P Kirwan
AIM: Functional high intensity training (F-HIT) is a novel fitness paradigm that integrates simultaneous aerobic and resistance training in sets of constantly varied movements, based on real-world situational exercises, performed at high intensity in workouts that range from ∼8-20 min/session. We hypothesized that F-HIT would be an effective exercise mode for reducing insulin resistance in type 2 diabetes (T2D). METHODS: We recruited 13 overweight/obese adults (5 males, 8 females; 53 ± 7 years; BMI 34...
May 15, 2018: Experimental Physiology
https://www.readbyqxmd.com/read/29761615/efficacy-and-safety-of-mk-1293-insulin-glargine-compared-with-originator-insulin-glargine-lantus-in-type-2-diabetes-a-randomized-open-label-clinical-trial
#7
Priscilla A Hollander, Wendy L Carofano, Raymond L H Lam, Gregory T Golm, Roy Eldor, Michael F Crutchlow, Michael C Marcos, Marc S Rendell, Philip D Home, Baptist Gallwitz, Julio Rosenstock
AIMS: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: This Phase 3, randomized, active-controlled, open-label, 24-week clinical trial enrolled 531 participants with T2DM (HbA1c ≤11.0%) eligible for or currently taking basal insulin (≥10 U/day). Participants were randomized 1:1 to once-daily Mk-Gla (n=263) or Sa-Gla (n=263). Titration of insulin was guided by a fasting plasma glucose (FPG)-based dosing algorithm...
May 14, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29744819/comparison-of-glycemic-variability-in-chinese-t2dm-patients-treated-with-exenatide-or-insulin-glargine-a-randomized-controlled-trial
#8
Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zhu
INTRODUCTION: Increasing the frequency of blood glucose monitoring aids the evaluation of glycemic variability and blood glucose control by antidiabetic drugs. It remains unclear, however, whether GLP-1 receptor agonists or basal insulin has a better effect on glycemic variability in type 2 diabetes mellitus (T2DM) patients who are inadequately controlled by metformin. We used a continuous glucose monitoring system (CGMS) to compare patients on a GLP-1 receptor agonist with patients on basal insulin in terms of glycemic variability...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29736187/-tcf7l2-correlation-in-both-insulin-secretion-and-postprandial-insulin-sensitivity
#9
Mari Cassol Ferreira, Maria Elizabeth Rossi da Silva, Rosa Tsuneshiro Fukui, Maria do Carmo Arruda-Marques, Rosa Ferreira Dos Santos
Background: The TCF7L2 rs7903146 variant is strongly associated with type 2 diabetes mellitus (T2DM). However, the mechanisms involved in this association remain unknown and may include extrapancreatic effects. The aim of this study was to perform a metabolic characterization of T2DM patients with and without the TCF7L2 rs7903146 risk T allele and analyze some influences of the TCF7L2 genotype on glucose metabolism. Methods: Patients with T2DM ( n  = 162) were genotyped for the TCF7L2 rs7903146 single nucleotide polymorphism...
2018: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/29732679/free-and-fixed-ratio-combinations-of-basal-insulin-and-glp-1-receptor-agonists-versus-basal-insulin-intensification-in-type-2-diabetes-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#10
Maria Ida Maiorino, Paolo Chiodini, Giuseppe Bellastella, Lorenzo Scappaticcio, Miriam Longo, Katherine Esposito, Dario Giugliano
We provide a meta-analysis of randomized controlled trials (RCTs) comparing free or fixed combination of a GLP-1RA plus basal insulin versus insulin intensification on metabolic control in patients with type 2 diabetes. We searched electronic databases for RCTs assessing changes in HbA1c, proportion of patients at HbA1c target of <7% (53 mmol/mol), hypoglycaemia, and weight change. We used a random-effect model to calculate the weighted mean difference (WMD) or relative risk (RR) with the 95% CI. We identified 11 RCTs, lasting 24-30 weeks, and involving 6176 patients...
May 7, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29726082/clinical-effectiveness-of-liraglutide-versus-basal-insulin-in-a-real-world-setting-evidence-for-improved-glycaemic-and-weight-control-in-obese-patients-with-type-2-diabetes
#11
Jetty Overbeek, Edith Heintjes, Eline Huisman, Christian Tikkanen, Arnout van Diermen, Fernie Penning-van Beest, Ron Herings
AIM: To compare real-world anti-diabetic treatment outcomes over 12 months in obese type 2 diabetes mellitus (T2DM) patients who previously received oral anti-diabetic (OAD) therapy and then initiated a first injectable therapy with liraglutide or basal insulin. MATERIALS AND METHODS: This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network. Adult obese (body mass index [BMI] ≥35 kg/m2 ) T2DM patients with ≥2 dispensing dates for liraglutide or basal insulin therapy (BOT) were selected...
May 3, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29725969/differences-in-glycemic-control-in-diabetic-and-non-diabetic-patients-with-parenteral-nutrition-using-a-basal-plus-correction-insulin-regimen-an-observational-retrospective-study
#12
Analía Ramos, Fernanda Rabasa, Lilian Mendoza, Joana Cardenete, Pedro Gill, Alba Morilla, Daniel Cardona, Antonio Pérez
INTRODUCTION: Hyperglycemia is a frequent complication of parenteral nutrition (PN) in patients both with and without diabetes mellitis (DM). The aim of this study was to evaluate the quality of glucose control achieved with basal plus-correction insulin in surgical patients with and without a history of DM receiving PN. METHODS: Retrospective evaluation of a protocol applied during the period of January 2013-December 2015. The insulin dose was started at 0.4 and 0...
May 3, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29720273/when-insulin-degludec-enhances-quality-of-life-in-patients-with-type-2-diabetes-a-qualitative-investigation
#13
James Weatherall, William H Polonsky, Sally Lanar, Naomi Knoble, Jonas Håkan-Bloch, Elisabeth Constam, Athena Philis-Tsimikas, Alexia Marrel
BACKGROUND: Anecdotal reports suggest that insulin degludec (IDeg) may offer unique health-related quality of life (HRQoL) benefits. As the nature of these benefits remain unclear, this study utilized qualitative research methods to investigate and elucidate the experience of "feeling better" after initiating IDeg. METHODS: Twenty adults with type 2 diabetes (T2D) who reported "feeling better" on IDeg for > 3 months participated in 90-min interviews...
May 3, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29719117/decreased-levels-of-keratin-8-sensitizes-mice-to-streptozotocin-induced-diabetes
#14
C M Alam, J S G Silvander, T O Helenius, D M Toivola
AIM: Diabetes is a result of an interplay between genetic, environmental and lifestyle factors. Keratin intermediate filaments are stress proteins in epithelial cells and keratin mutations predispose to several human diseases. However, the involvement of keratins in diabetes is not well known. K8 and its partner K18 are the main β-cell keratins, and knockout of K8 (K8-/- ) in mice causes mislocalization of glucose transporter 2, mitochondrial defects, reduced insulin content, and altered systemic glucose/insulin control...
May 2, 2018: Acta Physiologica
https://www.readbyqxmd.com/read/29718281/comprehensive-endocrine-metabolic-evaluation-of-patients-with-alstr%C3%A3-m-syndrome-compared-to-bmi-matched-controls
#15
Joan C Han, Daniela P Reyes-Capo, Chia-Ying Liu, James C Reynolds, Evrim Turkbey, Ismail Baris Turkbey, Joy Bryant, Jan D Marshall, Jürgen K Naggert, William A Gahl, Jack A Yanovski, Meral Gunay-Aygun
Background: Alström syndrome (AS), a monogenic form of obesity, is caused by recessive mutations in the centrosome- and basal body-associated gene, ALMS1. AS is characterized by retinal dystrophy, sensory hearing loss, cardiomyopathy, childhood obesity, and metabolic derangements. Objective: We sought to characterize the endocrine and metabolic features of AS while accounting for obesity as a confounder by comparing patients with AS to BMI-matched controls. Methods: We evaluated 38 patients with AS (age 2-38y) who were matched with 76 controls (age 2-48y) by age, sex, race, and BMI...
April 27, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29713962/devote-5-evaluating-the-short-term-cost-utility-of-insulin-degludec-versus-insulin-glargine-u100-in-basal-bolus-regimens-for-type-2-diabetes-in-the-uk
#16
Richard F Pollock, William J Valentine, Steven P Marso, Jens Gundgaard, Nino Hallén, Lars L Hansen, Deniz Tutkunkardas, John B Buse
INTRODUCTION: The aim of this study was to evaluate the short-term cost-utility of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) for the treatment of type 2 diabetes in the basal-bolus subgroup of the head-to-head cardiovascular (CV) outcome trial, DEVOTE. METHODS: A cost-utility analysis was conducted over a 2-year time horizon using a decision analytic model to compare costs in patients receiving once daily degludec or glargine U100, both as part of a basal-bolus regimen, in addition to standard care...
April 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29713961/a-systematic-literature-review-and-network-meta-analysis-comparing-once-weekly-semaglutide-with-other-glp-1-receptor-agonists-in-patients-with-type-2-diabetes-previously-receiving-basal-insulin
#17
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic
INTRODUCTION: Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutide as an add-on to basal insulin vs other GLP-1 receptor agonists (GLP-1 RAs) is available. The aim of this study was to conduct a network meta-analysis (NMA) to assess the efficacy and safety of once-weekly semaglutide vs other GLP-1 RAs in patients with T2D inadequately controlled on basal insulin...
April 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29707875/a-practical-approach-and-algorithm-for-intensifying-beyond-basal-insulin-in-type-2-diabetes
#18
REVIEW
Ronald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, Irving S Gottesman, Jean-François Yale
Despite the availability of long-term data demonstrating the benefits of timely and aggressive intensification of antihyperglycaemic regimens among individuals with type 2 diabetes, intensification beyond basal insulin continues to be suboptimal and a global challenge. This review summarises the evidence surrounding the various options of advancing glucose-lowering management beyond basal insulin and provides a practical algorithm to assist in optimising patient care and enhancing glycaemic target achievements...
April 29, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29702445/insulin-treatment-partially-prevents-cognitive-and-hippocampal-alterations-as-well-as-glucocorticoid-dysregulation-in-early-onset-insulin-deficient-diabetic-rats
#19
Nathalie Marissal-Arvy, Marie-Neige Campas, Audrey Semont, Céline Ducroix-Crepy, Marie-Christine Beauvieux, Julie Brossaud, Jean-Benoit Corcuff, Jean-Christophe Helbling, Sylvie Vancassel, Anne-Karine Bouzier-Sore, Katia Touyarot, Guillaume Ferreira, Pascal Barat, Marie-Pierre Moisan
The diagnosis of Type 1 Diabetes (T1D) in ever younger children led us to question the impact of insulin deficiency or chronic hyperglycemia on cerebral development and memory performances. Here, we sought abnormalities in these traits in a model of streptozotocin-induced diabetes in juvenile rats treated or not by insulin. We made the assumption that such alterations would be related, at least in part, to excessive glucocorticoid exposition in hippocampal neurons. We have compared 3 groups of juvenile rats: controls, untreated diabetics and insulin-treated diabetics...
April 17, 2018: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29700772/cost-effectiveness-of-insulin-degludec-versus-insulin-glargine-u100-in-patients-with-type-1-and-type-2-diabetes-mellitus-in-serbia
#20
Nebojša Lalić, Monika Russel-Szymczyk, Marina Culic, Christian Klyver Tikkanen, Barrie Chubb
INTRODUCTION: This study investigates the cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes mellitus in Serbia. METHODS: A cost-utility analysis, implementing a simple short-term model, was used to compare treatment costs and outcomes with degludec versus glargine U100 in patients with type 1 (T1DM) and type 2 diabetes (T2DM). Cost-effectiveness was analysed in a 1-year setting, based on data from clinical trials...
April 26, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
keyword
keyword
32685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"